<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: operations", fill: "#343434"},
{source: "2: operations", target: "2: various risks", fill: "#343434"},
{source: "2: various risks", target: "2: uncertainties", fill: "#343434"},
{source: "2: operations", target: "17: Moreover ", fill: "#800020"},
{source: "17: Moreover ", target: "17: adversely", fill: "#800020"},
{source: "17: adversely", target: "17: company could", fill: "#800020"},
{source: "17: company could", target: "17: disruptions with customers", fill: "#800020"},
{source: "17: disruptions with customers", target: "17: cost reduction", fill: "#800020"},
{source: "17: cost reduction", target: "17: restructuring efforts prove ineffective", fill: "#800020"},
{source: "17: Moreover ", target: "27: government", fill: "#967117"},
{source: "27: government", target: "27: reimbursement", fill: "#967117"},
{source: "27: reimbursement", target: "27: levels could", fill: "#967117"},
{source: "27: levels could", target: "27: negatively impact", fill: "#967117"},
{source: "27: negatively impact", target: "27: profitability", fill: "#967117"},
{source: "27: government", target: "47: Difficulties ", fill: "#dcdcdc"},
{source: "47: Difficulties ", target: "47: implementing", fill: "#dcdcdc"},
{source: "47: Difficulties ", target: "66: Certain ", fill: "#fdee00"},
{source: "66: Certain ", target: "66: selling products internationally", fill: "#fdee00"},
{source: "66: selling products internationally", target: "66: difficulties", fill: "#fdee00"},
{source: "66: difficulties", target: "66: agreements", fill: "#fdee00"},
{source: "66: agreements", target: "66: receivables", fill: "#fdee00"},
{source: "66: receivables", target: "66: through certain foreign legal systems", fill: "#fdee00"},
{source: "66: through certain foreign legal systems", target: "66: foreign customers", fill: "#fdee00"},
{source: "66: foreign customers", target: "66: longer payment cycles than customers", fill: "#fdee00"},
{source: "66: longer payment cycles than customers", target: "66: United States ", fill: "#fdee00"},
{source: "66: United States ", target: "66: United States ", fill: "#fdee00"},
{source: "66: United States ", target: "66: requirements", fill: "#fdee00"},
{source: "66: requirements", target: "66: restrictions", fill: "#fdee00"},
{source: "66: restrictions", target: "66: affiliated", fill: "#fdee00"},
{source: "66: affiliated", target: "66: conditions", fill: "#fdee00"},
{source: "66: conditions", target: "66: organization", fill: "#fdee00"},
{source: "66: organization", target: "66: throughout various countries", fill: "#fdee00"},
{source: "66: throughout various countries", target: "66: intellectual", fill: "#fdee00"},
{source: "66: intellectual", target: "66: intellectual property rights protection", fill: "#fdee00"},
{source: "66: intellectual property rights protection", target: "66: compliance with", fill: "#fdee00"},
{source: "66: compliance with", target: "66: foreign laws", fill: "#fdee00"},
{source: "66: foreign laws", target: "66: regulations", fill: "#fdee00"},
{source: "66: Certain ", target: "START_HERE", fill: "#fdee00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Collaborate</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_director">Operations director</a></td>
      <td>The role of operations director generally encompasses the oversight of operational aspects of company strategy with responsibilities to ensure operation information is supplied to the chief executive and the board of directors as well as external parties.\n\n\n== Description ==\nThe role of operations director can vary according to the size of a company, and at some companies many even encompass some or all the functions of a chief operating officer.The Institute of Directors of the United Kingdom defines the role as overseeing "all operational aspects of company strategy" and "responsible for the flow of operations information to the chief executive, the board and, where necessary, external parties such as investors or financial institutions".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Uncertainty">Uncertainty</a></td>
      <td>Uncertainty refers to epistemic situations involving imperfect or unknown information. It applies to predictions of future events, to physical measurements that are already made, or to the unknown.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Propagation_of_uncertainty">Propagation of uncertainty</a></td>
      <td>In statistics, propagation of uncertainty (or propagation of error) is the effect of variables' uncertainties (or errors, more specifically random errors) on the uncertainty of a function based on them. When the variables are the values of experimental measurements they have uncertainties due to measurement limitations (e.g., instrument precision) which propagate due to the combination of variables in the function.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Measurement_uncertainty">Measurement uncertainty</a></td>
      <td>In metrology, measurement uncertainty is the expression of the statistical dispersion of the values attributed to a measured quantity. All measurements are subject to uncertainty and a measurement result is complete only when it is accompanied by a statement of the associated uncertainty, such as the standard deviation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knightian_uncertainty">Knightian uncertainty</a></td>
      <td>In economics, Knightian uncertainty is a lack of any quantifiable knowledge about some possible occurrence, as opposed to the presence of quantifiable risk (e.g., that in statistical noise or a parameter's confidence interval). The concept acknowledges some fundamental degree of ignorance, a limit to knowledge, and an essential unpredictability of future events.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Uncertainty_parameter">Uncertainty parameter</a></td>
      <td>The uncertainty parameter U is a parameter introduced by the Minor Planet Center (MPC) to quantify concisely the uncertainty of a perturbed orbital solution for a minor planet. The parameter is a logarithmic scale from 0 to 9 that measures the anticipated longitudinal uncertainty in the minor planet's mean anomaly after 10 years.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Uncertainty_budget">Uncertainty budget</a></td>
      <td>The uncertainty budget is an aid for specifying the expanded measurement uncertainty. The individual measurement uncertainty factors are summarised, usually in tabular form, in the measurement uncertainty budget.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse">Adverse</a></td>
      <td>Adverse or adverse interest, in law, is anything that functions contrary to a party's interest. This word should not be confused with averse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_effect">Adverse effect</a></td>
      <td>An adverse effect is an undesired harmful effect resulting from a medication or other intervention, such as surgery. An adverse effect may be termed a "side effect", when judged to be secondary to a main or therapeutic effect.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_possession">Adverse possession</a></td>
      <td>Adverse possession, sometimes colloquially described as "squatter's rights", is a legal principle in the Anglo-American common law under which a person who does not have legal title to a piece of property—usually land (real property)—may acquire legal ownership based on continuous possession or occupation of the property without the permission (licence) of its legal owner. The possession by a person is not adverse if they are in possession as a tenant or licensee of the legal owner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_food_reaction">Adverse food reaction</a></td>
      <td>An adverse food reaction is an adverse response by the body to food or a specific type of food.The most common adverse reaction is a food allergy, which is an adverse immune response to either a specific type or a range of food proteins.\nHowever, other adverse responses to food are not allergies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anthony_Adverse">Anthony Adverse</a></td>
      <td>Anthony Adverse is a 1936 American epic historical drama film directed by Mervyn LeRoy and starring Fredric March and Olivia de Havilland. The screenplay by Sheridan Gibney draws elements of its plot from eight of the nine books in Hervey Allen's historical novel, Anthony Adverse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_(film)">Adverse (film)</a></td>
      <td>Adverse is a 2020 American crime thriller film written and directed by Brian Metcalf and starring Thomas Nicholas, Lou Diamond Phillips, Sean Astin, Kelly Arjen, Penelope Ann Miller, and Mickey Rourke. It premiered at the Fantasporto Film Festival, Portugal's largest film festival, on February 28, 2020.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adverse_party">Adverse party</a></td>
      <td>An adverse party is an opposing party in a lawsuit under an adversary system of law.  In general, an adverse party is a party against whom judgment is sought or "a party interested in sustaining a judgment or decree." For example, the adverse party for a defendant is the plaintiff.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hostile_witness">Hostile witness</a></td>
      <td>A hostile witness, also known as an adverse witness or an unfavorable witness, is a witness at trial whose  testimony on direct examination is either openly antagonistic or appears to be contrary to the legal position of the party who called the witness. This concept is used in the legal proceedings in the United States, and analogues of it exist in other legal systems in Western countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_reimbursement_account">Health reimbursement account</a></td>
      <td>A Health Reimbursement Account, formally a Health Reimbursement Arrangement (HRA), is a type of US employer-funded health benefit plan that reimburses employees for out-of-pocket medical expenses and, in limited cases, to pay for health insurance plan premiums.An HRA is not truly an account, since it does not place funds under a separate legal title. Instead, it is an agreement under which the employee can submit qualified health expenses to the employer for reimbursement.Following implementation of the Affordable Care Act, HRAs must be integrated with a qualified employer-sponsored group health insurance plan to avoid excise tax penalties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fee_Reimbursement_Scheme_(Andhra_Pradesh)">Fee Reimbursement Scheme (Andhra Pradesh)</a></td>
      <td>The Fee Reimbursement Scheme (also known as the Post-matric Scholarship Scheme) is a student education sponsorship programme of the Government of Andhra Pradesh. It supports students from lower economic strata in the state.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Learning_difficulties">Learning difficulties</a></td>
      <td>Learning disability, learning disorder, or learning difficulty (British English) is a condition in the brain that causes difficulties comprehending or processing information and can be caused by several different factors.  Given the "difficulty learning in a typical manner", this does not exclude the ability to learn in a different manner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dyslexia">Dyslexia</a></td>
      <td>Dyslexia, also known as reading disorder, is a disorder characterized by reading below the expected level for their age. Different people are affected to different degrees.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Breastfeeding_difficulties">Breastfeeding difficulties</a></td>
      <td>Breastfeeding difficulties refers to problems that arise from breastfeeding, the feeding of an infant or young child with milk from a woman's breasts.  Although babies have a sucking reflex that enables them to suck and swallow milk, and human breast milk is usually the best source of nourishment for human infants, there are circumstances under which breastfeeding can be problematic, or even in rare instances, contraindicated.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Degree_of_difficulty">Degree of difficulty</a></td>
      <td>Degree of difficulty (DD, sometimes called tariff or grade) is a concept used in several sports and other competitions to indicate the technical difficulty of a skill, performance, or course, often as a factor in scoring. Sports which incorporate a degree of difficulty in scoring include bouldering, cross-country skiing, diving, equestrianism, figure skating, freestyle skiing, gymnastics, rhythmic gymnastics, surfing, synchronized swimming and trampoline.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Desirable_difficulty">Desirable difficulty</a></td>
      <td>A desirable difficulty is a learning task that requires a considerable but desirable amount of effort, thereby improving long-term performance. It is also described as a learning level achieved through a sequence of learning tasks and feedback that lead to enhanced learning and transfer.As the name suggests, desirable difficulties should be highly desirable and increasingly challenging.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual">Intellectual</a></td>
      <td>An intellectual is a person who engages in critical thinking, research, and reflection about the reality of society, and who proposes solutions for the normative problems of society. Coming from the world of culture, either as a creator or as a mediator, the intellectual participates in politics, either to defend a concrete proposition or to denounce an injustice, usually by either rejecting or producing or extending an ideology, and by defending a system of values.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectualism">Intellectualism</a></td>
      <td>Intellectualism is the mental perspective that emphasizes the use, the development, and the exercise of the intellect; and also identifies the life of the mind of the intellectual person. In the field of philosophy, "intellectualism" is synonymous with rationalism, knowledge derived from reason.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectualization">Intellectualization</a></td>
      <td>In psychology, intellectualization is a defense mechanism by which reasoning is used to block confrontation with an unconscious conflict and its associated emotional stress – where thinking is used to avoid feeling. It involves emotionally removing one's self from a stressful event.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_virtue">Intellectual virtue</a></td>
      <td>Intellectual virtues are qualities of mind and character that promote intellectual flourishing, critical thinking, and the pursuit of truth. They include: intellectual responsibility, perseverance, open-mindedness, empathy, integrity, intellectual courage, confidence in reason, love of truth, intellectual humility, imaginativeness, curiosity, fair-mindedness, and autonomy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_honesty">Intellectual honesty</a></td>
      <td>Intellectual honesty is an applied method of problem solving, characterised by an unbiased, honest attitude, which can be demonstrated in a number of different ways:\n\nOne's personal beliefs or politics do not interfere with the pursuit of truth;\nRelevant facts and information are not purposefully omitted even when such things may contradict one's hypothesis;\nFacts are presented in an unbiased manner, and not twisted to give misleading impressions or to support one view over another;\nReferences, or earlier work, are acknowledged where possible, and plagiarism is avoided.Harvard ethicist Louis M. Guenin describes the "kernel" of intellectual honesty to be "a virtuous disposition to eschew deception when given an incentive for deception".Intentionally committed fallacies in debates and reasoning are called intellectual dishonesty.\n\n\n== See also ==\nAcademic honesty\nConflict of interest\nEpistemic feedback\nGood faith\nIntellectual\nList of fallacies\nScientific method\nSophism\nSystemic bias\n\n\n== References ==\nNotes\n\nFurther reading\n\nToledo-Pereyra, Luis H. (2002).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_functioning">Intellectual functioning</a></td>
      <td>Intellectual functioning refers to the "general mental ability that includes reasoning, planning, problem solving, abstract thinking, comprehending complex ideas, learning quickly and learning from experience". Significantly limited or impaired intellectual functioning characterizes intellectual disabilities.Ageing has been shown to cause a decline in intellectual functioning.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_giftedness">Intellectual giftedness</a></td>
      <td>Intellectual giftedness is an intellectual ability significantly higher than average. It is a characteristic of children, variously defined, that motivates differences in school programming.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>INVACARE CORP    Item 1A  <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>- -----------------------  The  companyapstas  business,  <font color="blue">operations</font>  and  financial  condition  are subject to  <font color="blue">various risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the risks and <font color="blue">uncertainties</font>  described below,  together  with all of the other  information  in this annual report on Form 10-K  and in the companyapstas  other <font color="blue">filings with</font> the SEC,  before making any  <font color="blue">investment</font>  <font color="blue">decision with respect</font> to the companyapstas  securities</td>
    </tr>
    <tr>
      <td>The risks and <font color="blue">uncertainties</font>  described below may not be the only ones the <font color="blue">company faces</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and  <font color="blue">uncertainties</font>  not <font color="blue">presently known by</font> the company or that the company  currently  deems <font color="blue">immaterial may also affect</font> the companyapstas  business</td>
    </tr>
    <tr>
      <td>If any of these known  or unknown  risks or  <font color="blue">uncertainties</font>  actually  occur or develop,  the  companyapstas  business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and <font color="blue">future growth prospects</font>  could change</td>
    </tr>
    <tr>
      <td>The  <font color="blue">consolidation</font> of <font color="blue">health care customers</font> and the companyapstas  <font color="blue"><font color="blue">competitors</font> could</font>  result in a loss of customers or in <font color="blue"><font color="blue">competitive</font> <font color="blue">pricing pressures</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Numerous  </font>initiatives and <font color="blue">reforms initiated by legislators</font>,  <font color="blue">regulators</font> and  third-party payors to reduce HME costs have resulted in a <font color="blue">consolidation</font> trend in  the home medical  equipment  <font color="blue">industry as well as among</font> the companyapstas  customers,  including <font color="blue">home health care</font>  providers</td>
    </tr>
    <tr>
      <td>Some of the companyapstas  <font color="blue">competitors</font>  have  been able to reduce  production  costs and have lowered the  purchase  prices of  their products in an effort to attract  customers</td>
    </tr>
    <tr>
      <td>This in turn has resulted in  greater  pricing   pressures,   including   pressure  to  offer  customers  more  <font color="blue">competitive</font> pricing terms, and the exclusion of <font color="blue">certain suppliers from important</font>  <font color="blue">market segments as</font> group purchasing <font color="blue"><font color="blue">organization</font>s</font>, in<font color="blue">dependent</font> delivery networks  and large <font color="blue">single accounts continue</font> to <font color="blue">consolidate</font>  <font color="blue">purchasing <font color="blue">decisions</font></font> for some  of the  companyapstas  customers</td>
    </tr>
    <tr>
      <td><font color="blue">Further  </font><font color="blue">consolidation</font>  could result in a loss of  customers, including <font color="blue">increased collectibility risks</font>, or in increased <font color="blue">competitive</font>  <font color="blue">pricing pressures</font></td>
    </tr>
    <tr>
      <td>If the  companyapstas  cost  reduction  efforts are  <font color="blue">ineffective</font>,  the  revenues and  <font color="blue">profitability</font> of the <font color="blue">company could</font> be <font color="blue"><font color="blue">negatively impact</font>ed</font></td>
    </tr>
    <tr>
      <td>The  company  may  not  be  successful  in  achieving   expected  operating  <font color="blue">efficiencies</font>  and  operating  cost  <font color="blue">reductions</font>,   and  may  experience  business  <font color="blue">disruptions</font>,  <font color="blue">associated with</font> its <font color="blue">previously</font>  announced  <font color="blue">restructuring</font>  and cost  <font color="blue">reduction <font color="blue">activities</font></font>,  including the <font color="blue">restructuring</font>  <font color="blue">activities</font> announced in July  2005 and, in  particular,  the companyapstas  <font color="blue">facility</font>  <font color="blue">consolidation</font>s  initiated in  <font color="blue">connection</font>  with  these  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>These  efforts  may not  produce  the full  <font color="blue">efficiency</font> and <font color="blue"><font color="blue">cost reduction</font> benefits</font> that the company expects</td>
    </tr>
    <tr>
      <td>Further,  such  benefits  may be realized  <font color="blue">later than</font>  expected,  and the costs of  <font color="blue">implementing</font>  these  measures  may be greater  than  anticipated</td>
    </tr>
    <tr>
      <td>If these  measures  are not  successful,  the <font color="blue">company may</font> undertake <font color="blue">additional <font color="blue">cost reduction</font> efforts</font>,  which  could result in <font color="blue">future charges</font></td>
    </tr>
    <tr>
      <td>Moreover,  the companyapstas ability to achieve its  other  strategic  goals and  business  plans may be  <font color="blue">adversely</font>  affected and the  <font color="blue">company could</font>  experience  business  <font color="blue">disruptions</font> with customers and elsewhere if  its <font color="blue">cost reduction</font> and <font color="blue">restructuring</font> efforts prove <font color="blue">ineffective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Decreased  </font><font color="blue">availability</font>  or increased  costs of <font color="blue"><font color="blue">raw materials</font> could increase</font> the  companyapstas costs of producing its products</td>
    </tr>
    <tr>
      <td>The company  <font color="blue">purchases raw</font>  materials,  <font color="blue">fabricated</font>  <font color="blue">components</font> and services  from a variety of suppliers</td>
    </tr>
    <tr>
      <td>Raw materials such as plastics, steel, and aluminum  are  considered  key raw  materials</td>
    </tr>
    <tr>
      <td>Where  <font color="blue">appropriate</font>,  the  company  employs  <font color="blue">contracts with</font> its suppliers,  <font color="blue">both domestically</font> and from the Far East</td>
    </tr>
    <tr>
      <td>In those  situations in <font color="blue">which contracts</font> are not  <font color="blue">advantageous</font>,  the company  believes that  its  <font color="blue">relationships</font>  with its suppliers  are  satisfactory  and that  <font color="blue">alternative</font>  sources of supply are <font color="blue">readily available</font></td>
    </tr>
    <tr>
      <td>From time to time, however, the prices  and <font color="blue">availability</font> of these <font color="blue">raw materials</font>  <font color="blue">fluctuate due</font> to <font color="blue">global market demands</font>,  <font color="blue">which could impair</font> the  companyapstas  ability to procure  <font color="blue">necessary</font>  materials,  or  increase the cost of <font color="blue">such materials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inflationary  </font>and other increases in costs  of these raw  materials  have  occurred  in the past and may recur  from time to  time</td>
    </tr>
    <tr>
      <td>In addition,  freight costs <font color="blue">associated with</font> shipping and receiving product  and sales are <font color="blue">impacted by</font>  <font color="blue"><font color="blue">fluctuation</font>s</font>  in the cost of oil and gas</td>
    </tr>
    <tr>
      <td>A reduction  in the supply or increase in the cost of those raw  materials  could  impact the  companyapstas  ability to  <font color="blue">manufacture</font>  its products and could  increase the cost of  production</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">government</font> and other  third-party  payor  <font color="blue">reimbursement</font>  <font color="blue">levels could</font>  <font color="blue">negatively impact</font> the companyapstas revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The  companyapstas  products  are sold  through a network of  specialized  home  health care providers, extended care facilities,  hospital and HMO-based stores,  and other  providers</td>
    </tr>
    <tr>
      <td>Many of those  providers  (the  companyapstas  customers) are  reimbursed for the <font color="blue">healthcare services provided</font> to their patients by third-party  payors, such as <font color="blue">government</font>  programs,  including Medicare and Medicaid,  private  insurance  plans and <font color="blue">managed care</font>  programs</td>
    </tr>
    <tr>
      <td>Many of these programs set maximum  <font color="blue">reimbursement</font>  levels for  certain of the  products  sold by the  company in the  United States</td>
    </tr>
    <tr>
      <td>If  third-party  <font color="blue">payors deny</font>  coverage,  make the  <font color="blue">reimbursement</font>  process or  <font color="blue">documentation</font>  <font color="blue">requirements</font>  more  uncertain or reduce their current  levels of <font color="blue">reimbursement</font>, or if the companyapstas costs of <font color="blue">production increase faster</font>  <font color="blue">than increases</font> in  <font color="blue">reimbursement</font>  levels,  the <font color="blue">company may</font> be unable to sell its  <font color="blue">products through</font> its <font color="blue">distribution channels on</font> a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>In  particular,  reduced  <font color="blue">government</font>  <font color="blue">reimbursement</font>  levels and  changes in  <font color="blue">reimbursement</font>  policies  could  add  pressure  to  the  companyapstas  revenues  and  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainty  </font>related to  Medicareapstas  <font color="blue">reimbursement</font>  policies for  power  <font color="blue">wheelchairs</font>  in  particular,  and  equipment  in general,  is expected to  continue into 2006</td>
    </tr>
    <tr>
      <td><font color="blue">The Centers for Medicare and Medicaid Services </font>are scheduled  to issue a new rule on face-to-face  exams and  <font color="blue">documentation</font>  <font color="blue">requirements</font>  for  power  <font color="blue">wheelchairs</font>  and other mobility  <font color="blue">devices by</font> April 1, 2006, as well as new  <font color="blue">reimbursement</font> codes, possibly later in the year</td>
    </tr>
    <tr>
      <td>Additionally, the US <font color="blue">Congress </font> <font color="blue">recently passed</font> the Deficit  Reduction Act, which includes  <font color="blue">payment cuts</font> to home                                        I-14  <page>  oxygen that will take effect in January 2009 and <font color="blue">reductions</font> for certain  durable  <font color="blue">home medical equipment spending</font> that will take effect in 2007</td>
    </tr>
    <tr>
      <td>Finally, while it  is unclear  whether  <font color="blue">Congress </font>will enact the proposed  provisions  into law, the  <font color="blue">Medicare  </font>cuts  included in President  Bushapstas  fiscal year 2007 budget  proposal  include  <font color="blue">approximately</font>  dlra7dtta4  billion in cuts to home  oxygen  therapy and power  wheelchair  <font color="blue">reimbursement</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font>trends and concerns  are  occurring in the  states &amp;apos  Medicaid programs</td>
    </tr>
    <tr>
      <td>If unfavorable  <font color="blue">reimbursement</font>  policies or <font color="blue">budgetary</font>  cuts are  adopted,  they could  <font color="blue">adversely</font>  affect  the demand for the  companyapstas  products  by  customers  who <font color="blue">depend on</font>  <font color="blue">reimbursement</font>  by the  <font color="blue">government</font>-funded  programs</td>
    </tr>
    <tr>
      <td>The percentage of the companyapstas  <font color="blue">sales <font color="blue">dependent</font> on</font> Medicare or other  insurance  <font color="blue">programs may increase as</font> the portion <font color="blue">of the United States</font>  population  over  age  65  continues  to  grow,   making  the  company  more  vulnerable  to  <font color="blue">reimbursement</font>  level  <font color="blue">reductions</font>  by  these  <font color="blue"><font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reduced  </font><font color="blue">government</font>  <font color="blue">reimbursement</font>  levels also could result in reduced  <font color="blue">private payor</font>  <font color="blue">reimbursement</font>  levels  because  certain   third-party  payors  may  index  their  <font color="blue">reimbursement</font>  schedules to Medicare <font color="blue">fee schedules</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reductions </font>in <font color="blue">reimbursement</font> levels also may  affect the  <font color="blue">profitability</font>  of the companyapstas  customers and <font color="blue">ultimately force</font> some  <font color="blue">customers without strong financial resources</font> to go out of business</td>
    </tr>
    <tr>
      <td>Outside the United  States,  <font color="blue">reimbursement</font>  <font color="blue">systems vary</font>  <font color="blue">significantly</font>  by  country</td>
    </tr>
    <tr>
      <td>Many foreign markets have  <font color="blue">government</font>-managed  <font color="blue">health care systems</font> that  govern <font color="blue">reimbursement</font> for new <font color="blue">home health care</font> products</td>
    </tr>
    <tr>
      <td>The ability of hospitals  and other <font color="blue">providers supported by such systems</font> to purchase the companyapstas products  is  <font color="blue">dependent</font>,  in part,  upon  public  <font color="blue">budgetary</font>  <font color="blue">constraints</font></td>
    </tr>
    <tr>
      <td>Canada and some  European countries, for example, have tightened <font color="blue">reimbursement</font> rates</td>
    </tr>
    <tr>
      <td>If adequate  levels of <font color="blue">reimbursement</font> from third-party payors outside <font color="blue">of the United States</font> are  not obtained,  <font color="blue">international sales</font> of the companyapstas products may decline,  which  could <font color="blue">adversely</font> affect the companyapstas net sales and could have a material adverse  effect on the companyapstas business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties  </font>in  <font color="blue">implementing</font> a new Enterprise  Resource  Planning  system have  disrupted the companyapstas business</td>
    </tr>
    <tr>
      <td>Due to <font color="blue">complexities</font> and  business  process  changes  associated  with this  <font color="blue">implementation</font>,  the  company  <font color="blue">encountered</font> a number of issues related to the start-up of the system,  including  <font color="blue"><font color="blue">difficult</font>ies</font>  in processing  orders,  customer  <font color="blue">disruptions</font> and the loss of some  business</td>
    </tr>
    <tr>
      <td>While the company  believes  that the  <font color="blue"><font color="blue">difficult</font>ies</font>  associated  with  <font color="blue">implementing</font>  and  <font color="blue">stabilizing</font>  its ERP  system  were  temporary  and have  been  addressed,  there  can be no  assurance  that the  company  will not  experience  additional ongoing <font color="blue">disruptions</font> or in<font color="blue">efficiencies</font> in its business <font color="blue">operations</font> as a  result  of  this  new  system  <font color="blue">implementation</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  final  phase  <font color="blue">addressing</font>  the  companyapstas  <font color="blue">manufacturing</font>  system is planned  to be  implemented  during 2006</td>
    </tr>
    <tr>
      <td>The companyapstas success depends on its ability to design, <font color="blue">manufacture</font>, distribute,  and achieve  market  <font color="blue">acceptance</font>  of <font color="blue">new products with higher</font>  <font color="blue">functionality</font>  and  <font color="blue"><font color="blue">lower cost</font>s</font></td>
    </tr>
    <tr>
      <td>The company  sells its products to customers  primarily in markets that are  <font color="blue">characterized by technological</font> change,  <font color="blue">product innovation</font> and <font color="blue">evolving industry</font>  standards and in <font color="blue">which product price</font> is <font color="blue">increasingly</font>  the primary  <font color="blue">consideration</font>  in  customers &amp;apos   purchasing  <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td>The  company is  <font color="blue">continually</font>  engaged in  product  <font color="blue">development</font>  and  <font color="blue">improvement</font>  programs</td>
    </tr>
    <tr>
      <td>The <font color="blue">company must</font>  continue to  design and  improve  innovative  products,  <font color="blue">effectively</font>  distribute  and achieve  market  <font color="blue">acceptance</font>  of those  products,  and reduce the costs of  producing  its  products,  in order to <font color="blue">compete <font color="blue">successfully</font> with</font> the companyapstas  <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If  <font color="blue">competitors</font> &amp;apos   product <font color="blue">development</font>  <font color="blue"><font color="blue">capabilities</font> become</font> more <font color="blue">effective than</font> those  of the company,  if  <font color="blue">competitors</font> &amp;apos   new or improved  products are <font color="blue">accepted by</font> the  market  before the companyapstas  products,  or if  <font color="blue">competitors</font>  are able to produce  <font color="blue">products at</font> a <font color="blue">lower cost</font> and <font color="blue">thus offer products</font> for sale at a lower price,  the  companyapstas  business,  financial  condition,  and results of  operation  could be  <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The company  may be unable to  <font color="blue">successfully</font>  identify,  acquire,  and  integrate  <font color="blue">strategic <font color="blue">acquisition</font> candidates</font></td>
    </tr>
    <tr>
      <td>The companyapstas plans include identifying,  acquiring,  and <font color="blue">integrating</font> other  strategic  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>There are  various  reasons  for the  company to acquire  <font color="blue">businesses</font>  or  product   lines,   including   providing  new  products  or  new  <font color="blue">manufacturing</font>  and  service  <font color="blue">capabilities</font>,  to add new  customers,  to  increase  <font color="blue">penetration with existing customers</font>,  and to <font color="blue">expand into new geographic markets</font></td>
    </tr>
    <tr>
      <td>The companyapstas ability to <font color="blue">successfully</font> grow through <font color="blue">acquisition</font>s depends upon its  ability to identify, negotiate, complete and <font color="blue">integrate suitable <font color="blue">acquisition</font>s</font> and  to obtain any <font color="blue">necessary</font> financing</td>
    </tr>
    <tr>
      <td>The costs of acquiring other <font color="blue">businesses</font> could  increase if <font color="blue">competition</font> for <font color="blue"><font color="blue">acquisition</font> candidates increases</font></td>
    </tr>
    <tr>
      <td>Additionally, the  success of the  companyapstas  <font color="blue">acquisition</font>  strategy  is subject to other  risks and  costs, including the following:  o    the companyapstas  ability to realize  operating  <font color="blue">efficiencies</font>,  synergies,  or       other  benefits  expected  from an  <font color="blue">acquisition</font>,  and  possible  delays  in       realizing the benefits of the acquired company or products;  o    diversion of managementapstas time and <font color="blue">attention from</font> other business concerns;  o    <font color="blue"><font color="blue">difficult</font>ies</font> in retaining <font color="blue">key employees</font> of the acquired  <font color="blue">businesses</font> who are       <font color="blue">necessary</font> to manage these <font color="blue">businesses</font>;  o    <font color="blue"><font color="blue">difficult</font>ies</font> in maintaining  uniform  standards,  controls,  procedures and       <font color="blue">policies throughout</font> acquired companies;  o    adverse  <font color="blue">effects on</font>  existing  business  <font color="blue">relationships</font>  with  suppliers  or       customers;  o    the risks  associated  with the  <font color="blue">assumption</font> of  <font color="blue">contingent</font>  or  undisclosed       <font color="blue">liabilities</font> of <font color="blue">acquisition</font> targets; and  o    ability to <font color="blue">generate future cash flows</font> or the <font color="blue">availability</font> of financing</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">acquisition</font> could <font color="blue">materially</font> impair the companyapstas operating  results by causing the company to incur debt or requiring  the  <font color="blue">amortization</font>  of  <font color="blue">acquisition</font> expenses and acquired assets</td>
    </tr>
    <tr>
      <td>I-15  <page>  The  company is subject to certain  risks  inherent in  managing  and  operating  <font color="blue">businesses</font> in many <font color="blue">different foreign jurisdictions</font></td>
    </tr>
    <tr>
      <td>The company has significant international <font color="blue">operations</font>,  including <font color="blue">operations</font>  in  Australia,  New Zealand,  Asia,  and Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>risks are inherent in  operating and <font color="blue">selling products internationally</font>, including:       o    <font color="blue"><font color="blue">difficult</font>ies</font>  in  enforcing  <font color="blue">agreements</font>  and  collecting   <font color="blue">receivables</font>            <font color="blue">through certain foreign legal systems</font>;       o    <font color="blue">foreign customers</font> who may have <font color="blue">longer payment cycles than customers</font> in            the United States;       o    tax rates in certain  foreign  countries  that may exceed those in the            <font color="blue">United States </font>and foreign  earnings that may be subject to withholding            <font color="blue">requirements</font>;       o    the   imposition  of  tariffs,   exchange   controls  or  other  trade            <font color="blue">restrictions</font>  including  transfer pricing  <font color="blue">restrictions</font>  when products            produced in one country  are sold to an  <font color="blue">affiliated</font>  entity in another            country;       o    general  economic and  political  <font color="blue">conditions</font>  in  countries  where the            company operates or where end users of the companyapstas products reside;       o    <font color="blue"><font color="blue">difficult</font>ies</font>  associated  with  managing a large  <font color="blue">organization</font>  spread            <font color="blue">throughout various countries</font>;       o    <font color="blue"><font color="blue">difficult</font>ies</font>  in  enforcing  <font color="blue">intellectual</font>  property  rights and weaker            <font color="blue">intellectual</font> property rights protection in some countries; and       o    required <font color="blue">compliance with</font> a variety of <font color="blue">foreign laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The  companyapstas  revenues are subject to exchange  rate  <font color="blue"><font color="blue">fluctuation</font>s</font>  that could  <font color="blue">adversely</font> affect the companyapstas results of <font color="blue">operations</font> or <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td><font color="blue">Currency  </font>exchange  rates are subject to  <font color="blue">fluctuation</font>  due to,  among other  things,  changes  in  local,  regional,  or  global  economic  <font color="blue">conditions</font>,   the  imposition  of  currency  exchange  <font color="blue">restrictions</font>,   and  unexpected  changes  in  <font color="blue">regulatory</font> or taxation  <font color="blue">environments</font></td>
    </tr>
    <tr>
      <td>The functional  currency of the companyapstas  <font color="blue">subsidiaries</font>  outside the <font color="blue">United States </font>is the <font color="blue">predominant</font>  <font color="blue">currency used by</font> the  <font color="blue">subsidiaries</font> to transact  business</td>
    </tr>
    <tr>
      <td>Through its international  <font color="blue">operations</font>,  the  company is exposed to foreign  currency  <font color="blue"><font color="blue">fluctuation</font>s</font>,  and  changes in exchange  rates can have a <font color="blue">significant impact on net sales</font> and elements of cost</td>
    </tr>
    <tr>
      <td>The <font color="blue">company uses forward</font>  contracts to help reduce its exposure to exchange  rate  variation  risk</td>
    </tr>
    <tr>
      <td>Despite the companyapstas  efforts to mitigate  these risks,  however,  the  companyapstas  revenues  may be <font color="blue">adversely</font>  <font color="blue">affected by</font> exchange  rate  <font color="blue"><font color="blue">fluctuation</font>s</font></td>
    </tr>
    <tr>
      <td>The  company  also is  exposed  to market  risk  through  various  <font color="blue">financial instruments</font>,  including fixed rate and <font color="blue">floating rate debt instruments</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">company uses interest</font>  swap  <font color="blue">agreements</font> to mitigate its exposure to interest  rate <font color="blue"><font color="blue">fluctuation</font>s</font>, but those <font color="blue">efforts may</font> not <font color="blue">adequately protect</font> the <font color="blue">company from</font>  <font color="blue">significant interest rate risks</font></td>
    </tr>
    <tr>
      <td>The  company  may  be  <font color="blue">adversely</font>   affected  by  legal   actions  or  <font color="blue">regulatory</font>  <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">company may</font> be subject to claims,  <font color="blue">litigation</font> or other <font color="blue">liabilities</font> as a  result of injuries caused <font color="blue">by allegedly</font> defective  products,  <font color="blue">acquisition</font>s it has  completed or in the <font color="blue">intellectual</font>  <font color="blue">property area</font></td>
    </tr>
    <tr>
      <td>For example, the <font color="blue">company may</font> be  exposed to future  <font color="blue">litigation</font> by third parties  <font color="blue">based on</font>  <font color="blue">intellectual</font>  property  <font color="blue">infringement</font> claims similar to the ongoing and <font color="blue">previously</font> disclosed  <font color="blue">Respironics  </font><font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any such claims or <font color="blue">litigation</font> against the company, regardless of the  merits, could result in substantial costs and <font color="blue">could harm</font> the companyapstas business</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property <font color="blue">litigation</font> or claims also could require the company:       o    to  cease   <font color="blue">manufacturing</font>   and  selling  any  of  its  products  that            <font color="blue">incorporate</font> the challenged <font color="blue">intellectual</font> property;       o    to obtain a license  from the  holder  of the  infringed  <font color="blue">intellectual</font>            property right alleged to have been  infringed,  <font color="blue">which license may</font> not            be <font color="blue">available on commercially reasonable terms</font>, if at all; or       o    to redesign  or rename its  products,  which may not be  possible  and            could be costly and time consuming</td>
    </tr>
    <tr>
      <td>The results of legal  <font color="blue">proceedings</font>  are <font color="blue">difficult</font> to predict and the company  <font color="blue">cannot provide</font> you with any assurance  that an action or proceeding  will not be  commenced  against  it, or that the company  will  prevail in any <font color="blue">such action</font> or  proceeding</td>
    </tr>
    <tr>
      <td>An unfavorable  resolution of any <font color="blue">legal action</font> or proceeding  could  <font color="blue">materially</font> and <font color="blue">adversely</font> affect the companyapstas  business,  results of <font color="blue">operations</font>,  liquidity or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The companyapstas  business and financial  <font color="blue">condition could</font> be <font color="blue">adversely</font>  <font color="blue">affected by</font>  the  <font color="blue"><font color="blue">difficult</font>ies</font>  in  acquiring  and  maintaining  a  <font color="blue">proprietary</font>  <font color="blue">intellectual</font>  <font color="blue">property ownership position</font></td>
    </tr>
    <tr>
      <td>The companyapstas  ability to compete  <font color="blue">effectively</font> with other <font color="blue">companies depends</font>  in part on the  companyapstas  ability to maintain and enforce its patents and other  <font color="blue">proprietary</font> rights,  which are essential to the companyapstas business</td>
    </tr>
    <tr>
      <td>The company  <font color="blue">relies on</font> a <font color="blue">combination</font> of patents, trade secrets,  know-how and <font color="blue">confidentiality</font>  <font color="blue">agreements</font> to protect the <font color="blue">proprietary</font> aspects of its <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These measures  <font color="blue">afford only</font> limited protection, and <font color="blue">competitors</font> may gain access to the companyapstas  <font color="blue">intellectual</font> property and <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>The law of patents and trade  secrets is  <font color="blue">constantly</font>  evolving and often  involves  complex  legal and factual  questions</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation  </font>has been and <font color="blue">may continue</font> to be <font color="blue">necessary</font> to enforce the  companyapstas  <font color="blue">intellectual</font> property rights, to protect the companyapstas trade secrets,  and to determine  the validity and scope of the  companyapstas  <font color="blue">proprietary</font>  rights</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">litigation</font>  can be costly and can divert  managementapstas  <font color="blue">attention from</font> the  growth of the business</td>
    </tr>
    <tr>
      <td>The <font color="blue">company cannot assure</font> you that its patents and other  <font color="blue">proprietary</font>  <font color="blue">rights will</font> not be <font color="blue">successfully</font>  challenged or that <font color="blue">others will</font> not  in<font color="blue">dependent</font>ly  develop  <font color="blue">substantially</font>  equivalent  information and <font color="blue">technology</font> or  <font color="blue">otherwise gain access</font> to the companyapstas <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
  </tbody>
</table>